登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码:000623 证券简称:吉林敖东 公告编号:2025-035 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 预计净利润为正值且属于下列情形之一： □扭亏为盈 R同向上升 □同向下降 二、与会计师事务所沟通情况 公司已就业绩预告有关事项与会计师事务所进行了预沟通，公司与会计师事务所在业绩预告方面不存在 分歧。本次业绩预告未经过注册会计师预审计。 三、业绩变动原因说明 报告期内，公司围绕市值管理，聚焦医药主业，持续提升经营质量，积极践行"专注于人、专精于药"的 企业价值观，实施 "大品种群、多品种群"的销售拉动政策，坚持走"医药+金融+大健康"多轮驱动快速 发展的道路，按照年初制定的估值提升计划有序推进各项工作，业绩取得大幅增长主要原因是公司公允 价值变动收益及投资收益同比增加。 一、本期业绩预计情况 1、业绩预告期间 2025年1月1日至2025年6月30日 2、业绩预告情况 1、上述数据为公司财务部门初步预计，公司2025年半年度业绩具体情况以公司发布的2025年半年度报 告数据为准。 2、关于公司 ...

Governance and Management - Jilin Aodong has received multiple governance honors, including the 2024 Excellent Board Practice Case, highlighting its commitment to corporate governance and operational performance improvement [2][3] - The company has established a robust governance structure and internal control management system to ensure accurate and complete information disclosure [2][3] Financial Performance - In 2024, the company achieved a revenue of CNY 261,057.51 million, a decrease of 24.31% compared to the previous year, while net profit attributable to shareholders increased by 6.27% to CNY 155,139.31 million [7][14] - The cost of the pharmaceutical segment decreased by 12.56% year-on-year, indicating effective cost management strategies [6][14] Business Segments - The three main business segments—traditional Chinese medicine, chemical pharmaceuticals, and retail pharmacy—generated a combined revenue of CNY 227,376.10 million, accounting for 87.10% of total revenue [7][11] - The traditional Chinese medicine segment alone contributed CNY 160,554.13 million, representing 61.50% of total revenue [7][9] Marketing and Sales Strategies - The company is enhancing its marketing system by integrating online sales through major e-commerce platforms and optimizing its offline stores for O2O business [5][11] - A focus on core product matrix development and strategic marketing initiatives has been implemented to improve sales performance and market penetration [10][11] Research and Development - In 2024, R&D investment amounted to CNY 99,909,053.79, a decrease of 29.69% from the previous year, with a focus on balancing R&D spending and cost control [17][19] - The company is actively pursuing innovation in traditional Chinese medicine and exploring new product development in various therapeutic areas [19][20] Shareholder Returns - The company plans to distribute a cash dividend of CNY 3 per 10 shares for 2024, reflecting a commitment to shareholder returns while balancing operational needs [12][13] - A three-year shareholder return plan has been established to enhance dividend frequency and optimize payout ratios [12][13] Challenges and Future Outlook - The company faces challenges such as declining revenue and increasing accounts receivable relative to revenue, prompting a focus on risk management and operational efficiency [16][21] - Future strategies include enhancing core product market share, expanding into international markets, and leveraging AI technology for operational improvements [20][21]